This Week in Ophthalmology — Sep 19, 2026

Welcome to This Week in Ophthalmology. This week we're covering 10 notable papers spanning vitreoretinal surgical decision-making, the systemic and diagnostic stakes of retinal disease, and prognostic markers in glaucoma and paediatric eye care. Let's dive in.

We start with three papers that all ask the same uncomfortable question: are we still doing things in the operating theatre out of habit? In the British Journal of Ophthalmology, Tzoumas and colleagues used the combined British, Irish and European vitreoretinal registry to compare sulphur hexafluoride, perfluoroethane and perfluoropropane in low-to-moderate complexity rhegmatogenous detachment, with nearly seven and a half thousand eyes contributing to the anatomical analysis and propensity matching to balance the groups [1]. Anatomical success was broadly similar across gases, with estimates leaning modestly in favour of perfluoroethane, but the striking signal was against the longest-acting agent. Perfluoropropane was associated with about a line of vision worse acuity than either other gas, with roughly triple the odds of cystoid macular oedema compared with sulphur hexafluoride, and raised pressure was less than half as likely with perfluoroethane as with perfluoropropane. This is registry data, so channelling by case complexity can never be fully excluded, but the practical message is that reaching for the long-acting gas in a straightforward detachment buys no demonstrable anatomical advantage and may cost the patient visually.

That theme continues in Ophthalmology Retina, where Al-Burak and colleagues synthesised fourteen studies and just under sixteen hundred eyes comparing fluorinated gas with plain room air after macular hole surgery [2]. Closure rates and final acuity did not differ significantly between gas and air, but the authors are refreshingly careful about what that does and does not mean. Only three of the fourteen studies were randomised, two of those at high risk of bias, heterogeneity was substantial, and certainty was rated very low for every outcome. The intervals around the closure estimate remain compatible with a clinically meaningful benefit of gas, the single non-inferiority trial did not establish air as non-inferior even in holes of 400 micrometres or smaller, and the only stratified data above 520 micrometres favoured gas. So air is a reasonable option in small and medium holes, but this is not permission to abandon gas in the large ones. Also in Ophthalmology Retina, Zhang and colleagues tackled adjunctive scleral buckling during primary vitrectomy for giant retinal tear detachments across eleven comparative studies [3]. Overall, adding a buckle did not improve single-surgery success, final anatomical success, or the proportion of eyes reaching 20/200 or better. A post hoc subgroup of studies with mean age under forty did show better single-surgery success with a buckle, but nine of eleven studies carried serious risk of bias, buckled eyes were more often phakic and had more proliferative vitreoretinopathy and inferior tears, and the evidence was graded very low quality. In other words, surgeons are selecting buckles for higher-risk eyes, and confounding, not benefit, may explain much of what we see.

Our second theme is what happens to the patient beyond the eye, and here Ophthalmology Retina delivers the week's most actionable paper. Vora and colleagues studied nearly fourteen hundred adults with ophthalmologist-confirmed acute embolic retinal artery occlusion presenting within thirty days of symptom onset in a large Northern California community system, using a self-controlled design where each patient served as their own comparator [4]. Stroke risk peaked on the day of presentation, running roughly six times the baseline rate overall and close to nine times higher in central retinal artery occlusion, and it remained about five to six times elevated across the first thirty days for both central and branch occlusions, with a modest excess persisting to one year. Notably, there was no statistically significant increase in myocardial infarction. The care gap is where this becomes practice-changing: within thirty days, about two thirds of patients with central occlusions underwent neuroimaging compared with under half of those with branch occlusions, and cardiac and carotid evaluation were similarly less frequent in the branch group. Branch retinal artery occlusion is not the benign cousin of central occlusion; it carries the same acute stroke hazard and deserves the same urgent stroke pathway referral.

Staying with retinal medical management, JAMA Ophthalmology published a prospective Thai multicentre cohort from Chaikitmongkol and colleagues examining what happens when you stop treating polypoidal choroidal vasculopathy after complete polypoidal regression [5]. Of 81 treatment-naive eyes given monthly aflibercept, only about 40 percent achieved complete regression by week 12 or 24. Among the regressed eyes followed on an as-needed regimen, half of the eyes recurred within two years, and the fluid-free probability plateaued near 55 percent by six months and stayed there out to eighty-four weeks. Recurrences were not trivial: median acuity loss from the prior visit was around three and a half letters, but three of fourteen recurrent eyes lost ten letters or more and five developed new haemorrhage. Complete regression is therefore a meaningful milestone but not a discharge, and these authors suggest post-treatment optical coherence tomography biomarkers may eventually separate eyes safe to defer from those needing continued therapy.

A third thread this week is diagnostic delay and its permanent cost. A systematic review in Ophthalmology Retina from Mikhail and colleagues collected 43 patients with ocular toxoplasmosis initially mistaken for acute retinal necrosis or cytomegalovirus retinitis [6]. About four in five patients were immunocompromised and roughly two thirds had prior corticosteroid exposure. The average diagnostic delay was about 26 days on ineffective antivirals, and the outcomes were sobering: more than half of the affected eyes ended with acuity worse than 20/200, and close to one in five progressed to light perception or worse, phthisis, or enucleation. This is case-report-level evidence with obvious publication bias, but the operational lesson is cheap to implement: in a necrotising retinitis in an immunocompromised or steroid-exposed patient, send intraocular fluid for polymerase chain reaction that includes toxoplasma, and do not give empiric corticosteroids without anti-toxoplasma cover. A parallel message comes from the American Journal of Ophthalmology, where Ortiz-Morales and colleagues reported a nationwide multicentre cohort of 228 eyes in chronic Stevens-Johnson syndrome [7]. The median delay to reaching a specialised centre was a full year, more than half of the eyes required surgery, most often mucous membrane grafting, and lid margin keratinisation raised the odds of needing surgery roughly eleven-fold while conjunctivalisation roughly tripled them. Longer disease duration and exposure to antibiotics or non-steroidal anti-inflammatories predicted progressive visual loss. Two lid signs on slit lamp should trigger early referral rather than watchful waiting.

Finally, three papers on prognosis and systems of care. In Ophthalmology, Yousef and colleagues reported two decades of centralised multidisciplinary retinoblastoma care at a single cancer centre, covering a thousand eyes in 601 children, most with bilateral disease and more than half referred from outside the country [8]. Five-year overall survival was 96 percent, globe salvage among conservatively treated eyes was about three quarters, ranging from 98 percent in Group A down to 17 percent in Group E, and metastasis occurred in about four percent. That is high-income-country performance delivered in a resource-limited setting through centralisation, capacity building and telemedicine twinning — a model worth citing when arguing for regionalised paediatric ocular oncology. In the British Journal of Ophthalmology, Panigrahi and colleagues reviewed over twelve hundred eyes with primary congenital glaucoma and found that optic disc cupping reversed after surgery in about 43 percent of eyes [9]. Each additional millimetre of baseline corneal diameter halved the odds of reversal, and neonatal or infantile onset roughly doubled them. Useful for counselling parents, and a reminder that a large cup in a young child is not necessarily fixed damage. And in the American Journal of Ophthalmology, Nishida and colleagues applied automated deep learning vasculometry to baseline fundus photographs in nearly sixteen hundred glaucoma suspect and open-angle glaucoma eyes followed a decade [10]. Higher venous and arterial fractal dimension and greater arterial tortuosity were each associated with slower visual field decline after adjustment for clinical factors. The effects were small, on the order of a few hundredths of a decibel per year per standard deviation, and the authors are explicit that independent validation is needed before anything here changes management.

If you only have time for one paper this week, make it the retinal artery occlusion study in Ophthalmology Retina [4]. It quantifies a stroke risk that peaks the very day your patient sits in your chair, and it shows we are systematically under-triaging branch occlusions — a gap any clinic can close tomorrow.

Here are the key takeaways from this week in Ophthalmology. Treat every acute retinal artery occlusion, branch or central, as an emergency stroke referral on the day of presentation. In routine rhegmatogenous detachment, long-acting perfluoropropane offers no anatomical advantage and is linked to worse acuity, more macular oedema and more pressure rise. Room air is defensible for small and medium macular holes, but the evidence is very low certainty and large holes may still need gas. Complete polypoidal regression in polypoidal choroidal vasculopathy does not mean cure, since half of the deferred eyes recur within two years, some with vision-threatening haemorrhage. And in necrotising retinitis, think toxoplasma early and test intraocular fluid before committing to empiric steroids.

That's your roundup for This Week in Ophthalmology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.